Search results for "Cardiology"

showing 10 items of 6064 documents

Transdermal estrogens do not appear to modify the extent of lesional areas of aortic atherosclerosis in oophorectomized rabbits on a cholesterol-rich…

2000

Cardiovascular disease (CVD) is the leading cause of death in older women in industrialised countries. It has been suggested that it is the cessation of estrogen production by the ovaries that puts postmenopausal women at increased risk of CVD. Estrogen therapy has demonstrated a protective effect against CVD and several reports suggest that diverse mechanisms may be involved. Oral estrogen appears to be associated with a better lipid profile than the use of transdermal estrogens; however, it is assumed that estrogens, oral and non-oral, have direct actions on the blood vessels that may exert an important role in cardiovascular disease prevention. To investigate the effect of transdermal es…

medicine.medical_specialtymedicine.drug_classArteriosclerosisOvariectomyAortic DiseasesPlaceboAdministration CutaneousCholesterol Dietarychemistry.chemical_compoundTransdermal estrogenInternal medicinemedicineAnimalsTreatment FailureTransdermalmedicine.diagnostic_testEstradiolVascular diseaseCholesterolbusiness.industrymedicine.diseaseEndocrinologychemistryEstrogenDisease ProgressionFemaleTroloxRabbitsCardiology and Cardiovascular MedicineLipid profilebusinessAtherosclerosis
researchProduct

CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure

2021

Abstract Background Intrarenal venous flow (IRVF) measured by Doppler ultrasound has gained interest as a potential surrogate marker of renal congestion and adverse outcomes in heart failure. In this work, we aimed to determine if antigen carbohydrate 125 (CA125) and plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) are associated with congestive IRVF patterns (i.e., biphasic and monophasic) in acute heart failure (AHF). Methods and results We prospectively enrolled a consecutive cohort of 70 patients hospitalized for AHF. Renal Doppler ultrasound was assessed within the first 24-h of hospital admission. The mean age of the sample was 73.5 ± 12.3 years; 47.1% were female, and…

medicine.medical_specialtymedicine.drug_classCarbohydrates030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVenous flow03 medical and health sciencesCA1250302 clinical medicineInterquartile rangeIntrarrenal Doppler ultrasoundInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumans030212 general & internal medicineHeart FailureOriginal Scientific PaperSurrogate endpointbusiness.industryCardiorenalMembrane ProteinsAcute heart failureGeneral Medicinemedicine.diseasePrognosisPeptide FragmentsROC CurveHeart failureCA-125 AntigenCohortNTproBNPCardiologyCongestionFemaleDoppler ultrasoundCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionBiomarkers
researchProduct

Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure

2009

The presence of a reciprocal link between inflammation and oxidative/nitrosative stress has been postulated in chronic heart failure (CHF). We aimed to determine signs of nitrosative stress in serum/plasma of CHF patients. ELISA tests were used for quantification of serum/plasma levels of Nitrotyrosine (NT), H(2)O(2), total NO, nitrite (NO(2)(-)), myeloperoxidase (MPO), Tumor Necrosis Factor-alpha (TNFalpha) and pro-Brain Natriuretic Peptide (proBNP) in 66 CHF patients (9 in NYHA I, 34 NYHA II, 23 NYHA III) and in 14 age-matched healthy subjects. NT levels were higher in NYHA III CHF patients compared to NYHA II (p<0.05), NYHA I (p<0.03) and controls (p<0.02), whereas NO(2)(-) and total NO …

medicine.medical_specialtymedicine.drug_classInflammationSystemic inflammationGastroenterologyNITROSATIVE STRESSchemistry.chemical_compoundInternal medicineBlood plasmamedicineNatriuretic peptidecardiovascular diseasesOXIDATIVE STRESSEndothelial dysfunctionbiologybusiness.industryNitrotyrosinemedicine.diseasehumanitiesEndocrinologychemistryMyeloperoxidaseHeart failureENDOTHELIAL DYSFUNCTIONcardiovascular systembiology.proteinmedicine.symptomCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiology
researchProduct

Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure.

2021

This study aimed to evaluate whether glomerular filtration rate (eGFR) during admission modifies the predictive value of plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP) and carbohydrate antigen 125 (CA125) in patients hospitalized for acute heart failure (AHF).We retrospectively evaluated 4595 patients consecutively discharged after admission for AHF at three tertiary-care hospitals from January 2008 through October 2019. To investigate the effect of kidney function on the association of NT-proBNP and CA125 with 1-year mortality (all-cause and cardiovascular mortality), we stratified patients according to four eGFR categories:30 mL•minAt 1-year follow-up, 748 of 4595 (16.3%)…

medicine.medical_specialtymedicine.drug_classRenal functionCardiorenal syndromeInternal medicineNatriuretic Peptide BrainInternal MedicineNatriuretic peptideMedicineHumansIn patientCardiovascular mortalityRetrospective StudiesHeart Failurebusiness.industryAfter dischargemedicine.diseasePrognosisPeptide FragmentsHeart failureCA-125 AntigenCardiologyRisk of deathbusinessBiomarkersGlomerular Filtration RateEuropean journal of internal medicine
researchProduct

Early Spot Urinary Sodium and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction

2020

&lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; In acute heart failure (AHF), early assessment of spot urinary sodium (U&lt;sub&gt;Na&lt;/sub&gt;) has emerged as a useful biomarker for risk stratification and monitoring. The objective of this study was to investigate (a) whether early spot U&lt;sub&gt;Na&lt;/sub&gt; predicts 24-h diuretic efficiency and (b) the clinical factors associated with early spot U&lt;sub&gt;Na&lt;/sub&gt; in patients with AHF and concomitant renal dysfunction (RD). &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; This is a post hoc analysis of the IMPROVE-HF trial, in which 160 patients with AHF and RD (estimated glomerular filtrate rate [eGFR] &amp;#x3c;60 mL/min/1…

medicine.medical_specialtymedicine.drug_classUrologymedicine.medical_treatmentUrologyInterquartile rangePost-hoc analysismedicineNatriuretic peptideHumansDiureticsAgedAged 80 and overHeart Failurebusiness.industrySodiumFurosemidemedicine.diseaseHeart failureConcomitantAcute DiseasePopulation studyKidney DiseasesDiureticCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiorenal Medicine
researchProduct

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

2020

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who hav…

medicine.medical_specialtymedicine.drug_classantithrombotic therapyCoronavirus disease 2019; SARS-CoV-2; anticoagulant; antiplatelet; antithrombotic therapy; thrombosisDisease030204 cardiovascular system & hematologyantiplateletPathogenesis03 medical and health sciences0302 clinical medicineAntithromboticEpidemiologyMedicine030212 general & internal medicinePlatelet activationEndothelial dysfunctionIntensive care medicinethrombosisCoronavirus disease 2019SARS-CoV-2business.industryanticoagulantAnticoagulantmedicine.diseaseThrombosisCardiology and Cardiovascular MedicinebusinessJournal of the American College of Cardiology
researchProduct

Papel de la antitrombina iii en cirugía cardiaca

2013

Coagulation of blood is of multidisciplinary interest. Cardiac surgery produces major changes in the delicate balance between pro-and anti-coagulant serum factors. The role of antithrombin iii has been analysed after finding evidence that associated decreased levels of protein activity to postoperative morbidity and mortality. Supplementing exogenous antithrombin is considered with the aim of optimising outcomes. Its intrinsic anticoagulant and anti-inflammatory properties have stimulated a growing interest, and suggests new lines of research.

medicine.medical_specialtymedicine.drug_classbusiness.industryAnticoagulantAntithrombinCritical Care and Intensive Care MedicineCardiac surgeryAnesthesiology and Pain MedicineCoagulationInternal medicinemedicineCardiologyProtein activitybusinessmedicine.drugRevista Española de Anestesiología y Reanimación
researchProduct

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

2020

Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for thrombolysis with recombinant tissue-type plasminogen activator (rt-PA). In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth. Aims To provide insights into the clinical use of idarucizumab in patients under effective dabigatran anticoagulation presenting with signs of acute ischemic stroke or intracranial hemorrhage. Methods Retrospective data collected from German neurological/neurosurgical departments ad…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMedizinAntibodies Monoclonal HumanizedAntithrombinsBrain IschemiaDabigatranGermanyInternal medicinemedicineHumansThrombolytic Therapyddc:610Ischemic StrokeRetrospective StudiesIntracerebral hemorrhagebusiness.industryAnticoagulantWarfarinIdarucizumabAtrial fibrillationThrombolysisVitamin K antagonistmedicine.diseaseDabigatranStrokeNeurologyCardiologybusinessIntracranial Hemorrhagesmedicine.drugInternational Journal of Stroke
researchProduct

Impact of Proportionality of Secondary Mitral Regurgitation on Outcome After Transcatheter Mitral Valve Repair

2020

The purpose of this paper was to evaluate the impact of proportionality of secondary mitral regurgitation (SMR) in a large real-world registry of transcatheter edge-to-edge mitral valve repair (TMVr) BACKGROUND: Differences in the outcomes of recent randomized trials of TMVr for SMR may be explained by the proportionality of SMR severity to left ventricular (LV) volume.The ratio of pre-procedural effective regurgitant orifice area (EROA) to LV end-diastolic volume (LVEDV) was retrospectively assessed in patients undergoing TMVr for severe SMR between 2008 and 2019 from the EuroSMR registry. A recently proposed SMR proportionality scheme was adapted to stratify patients according to EROA/LVE…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentRenal function030204 cardiovascular system & hematology030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineNatriuretic peptideHumansRadiology Nuclear Medicine and imagingRetrospective StudiesBody surface areaMitral valve repairMitral regurgitationEjection fractionbusiness.industryMortality rateMitral Valve Insufficiencymedicine.diseaseTreatment OutcomeHeart failureQuality of LifeCardiologyMitral ValveCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Imaging
researchProduct

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure

2020

AIMS: Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and is related with worse outcomes. Insulin treatment is associated with sodium and water retention, weight gain, and hypoglycaemia-all pathophysiological mechanisms related to HF decompensation. This study aimed to evaluate the association between insulin treatment and the risk of 1year readmission for HF in patients discharged for acute HF.; METHODS AND RESULTS: We prospectively included 2895 consecutive patients discharged after an episode of acute HF in a single tertiary hospital. Multivariable Cox regression, adapted for competing events, was used to assess the association between insulin treatment and …

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusOriginal Research ArticlesType 2 diabetes mellitusmedicineDiseases of the circulatory (Cardiovascular) systemDecompensation030212 general & internal medicineOriginal Research ArticleEjection fractionbusiness.industryProportional hazards modelInsulinHazard ratioType 2 Diabetes MellitusAcute heart failureHospital readmissionmedicine.diseaseHeart failureRC666-701Insulin therapyCardiology and Cardiovascular Medicinebusiness
researchProduct